• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

韩国全国范围内的宫颈癌筛查:来自国民健康保险服务癌症筛查项目和国家癌症筛查项目的数据,2009 - 2014年

Nationwide cervical cancer screening in Korea: data from the National Health Insurance Service Cancer Screening Program and National Cancer Screening Program, 2009-2014.

作者信息

Shim Seung Hyuk, Kim Hyeongsu, Sohn In Sook, Hwang Han Sung, Kwon Han Sung, Lee Sun Joo, Lee Ji Young, Kim Soo Nyung, Lee Kunsei, Chang Sounghoon

机构信息

Department of Obstetrics and Gynecology, Konkuk University School of Medicine, Seoul, Korea.

Department of Preventive Medicine, Konkuk University School of Medicine, Seoul, Korea.

出版信息

J Gynecol Oncol. 2017 Sep;28(5):e63. doi: 10.3802/jgo.2017.28.e63. Epub 2017 May 26.

DOI:10.3802/jgo.2017.28.e63
PMID:28657224
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5540722/
Abstract

OBJECTIVE

The rates of participation in the Korean nationwide cervical cancer screening program and the rates of abnormal test results were determined.

METHODS

The database of the National Health Insurance Service (NHIS) was used during the study period (2009-2014).

RESULTS

The participation rate increased from 41.10% in 2009 to 51.52% in 2014 (annual percentage change, 4.126%; 95% confidence interval [CI]=2.253-6.034). During the study period, women ≥70 years of age had the lowest rate of participation (range, 21.7%-31.9%) and those 30-39 years of age the second-lowest (27.7%-44.9%). The participation rates of National Health Insurance beneficiaries (range, 48.6%-52.5%) were higher than those of Medical Aid Program (MAP) recipients (29.6%-33.2%). The rates of abnormal results were 0.65% in 2009 and 0.52% in 2014, with a decreasing tendency in all age groups except the youngest (30-39 years). Every year the abnormal result rates tended to decrease with age, from the age groups of 30-39 years to 60-69 years but increased in women ≥70 years of age. The ratio of patients with atypical squamous cells of undetermined significance compared with those with squamous intraepithelial lesions increased from 2.71 in 2009 to 4.91 in 2014.

CONCLUSION

Differences related to age and occurring over time were found in the rates of participation and abnormal results. Further efforts are needed to encourage participation in cervical cancer screening, especially for MAP recipients, elderly women and women 30-39 years of age. Quality control measures for cervical cancer screening programs should be enforced consistently.

摘要

目的

确定韩国全国宫颈癌筛查项目的参与率和检查结果异常率。

方法

研究期间(2009 - 2014年)使用了国民健康保险服务(NHIS)的数据库。

结果

参与率从2009年的41.10%增至2014年的51.52%(年百分比变化为4.126%;95%置信区间[CI]=2.253 - 6.034)。研究期间,70岁及以上女性的参与率最低(范围为21.7% - 31.9%),30 - 39岁女性的参与率次之(27.7% - 44.9%)。国民健康保险受益人的参与率(范围为48.6% - 52.5%)高于医疗救助计划(MAP)受助者(29.6% - 33.2%)。2009年异常结果率为0.65%,2014年为0.52%,除最年轻组(30 - 39岁)外,所有年龄组的异常结果率均呈下降趋势。每年异常结果率往往随年龄增长而下降,从30 - 39岁年龄组到60 - 69岁年龄组,但70岁及以上女性的异常结果率有所上升。意义不明确的非典型鳞状细胞患者与鳞状上皮内病变患者的比例从2009年的2.71增至2014年的4.91。

结论

在参与率和异常结果率方面发现了与年龄及时间相关的差异。需要进一步努力鼓励参与宫颈癌筛查,尤其是针对MAP受助者、老年女性和30 - 39岁女性。应持续加强宫颈癌筛查项目的质量控制措施。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1750/5540722/9ebe892f1606/jgo-28-e63-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1750/5540722/9d4d4ba10129/jgo-28-e63-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1750/5540722/e5df24770b25/jgo-28-e63-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1750/5540722/9ebe892f1606/jgo-28-e63-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1750/5540722/9d4d4ba10129/jgo-28-e63-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1750/5540722/e5df24770b25/jgo-28-e63-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1750/5540722/9ebe892f1606/jgo-28-e63-g003.jpg

相似文献

1
Nationwide cervical cancer screening in Korea: data from the National Health Insurance Service Cancer Screening Program and National Cancer Screening Program, 2009-2014.韩国全国范围内的宫颈癌筛查:来自国民健康保险服务癌症筛查项目和国家癌症筛查项目的数据,2009 - 2014年
J Gynecol Oncol. 2017 Sep;28(5):e63. doi: 10.3802/jgo.2017.28.e63. Epub 2017 May 26.
2
Implementation rate and related factors of confirmatory tests following an abnormal Pap smear: a nationwide study from the National Health Insurance.巴氏涂片异常后行确认性检测的实施率及相关因素:来自国家健康保险的全国性研究。
J Gynecol Oncol. 2024 May;35(3):e26. doi: 10.3802/jgo.2024.35.e26. Epub 2023 Dec 18.
3
Prevalence of human papillomavirus genotypes and precancerous cervical lesions in a screening population in the Republic of Korea, 2014-2016.2014-2016 年韩国筛查人群中人类乳头瘤病毒基因型和宫颈癌前病变的流行情况。
J Gynecol Oncol. 2018 Jan;29(1):e14. doi: 10.3802/jgo.2018.29.e14.
4
Follow-up of women with cervical cytological abnormalities showing atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion: a nationwide cohort study.对显示意义不明确的非典型鳞状细胞或低级别鳞状上皮内病变的宫颈细胞学异常女性的随访:一项全国性队列研究。
Am J Obstet Gynecol. 2017 Jan;216(1):48.e1-48.e15. doi: 10.1016/j.ajog.2016.07.042. Epub 2016 Jul 25.
5
Frequency of high-grade squamous cervical lesions among women over age 65 years living with HIV.65 岁以上 HIV 感染者中高级别宫颈鳞状上皮内病变的频率。
Am J Obstet Gynecol. 2021 Oct;225(4):411.e1-411.e7. doi: 10.1016/j.ajog.2021.04.253. Epub 2021 May 3.
6
Benefit and burden in the Dutch cytology-based vs high-risk human papillomavirus-based cervical cancer screening program.荷兰基于细胞学与基于高危型人乳头瘤病毒的宫颈癌筛查项目中的获益与负担
Am J Obstet Gynecol. 2021 Feb;224(2):200.e1-200.e9. doi: 10.1016/j.ajog.2020.08.026. Epub 2020 Aug 13.
7
Performance of papanicolaou testing and detection of cervical carcinoma in situ in participants of organized cervical cancer screening in South Korea.韩国组织宫颈癌筛查参与者巴氏涂片检测和宫颈原位癌检测的性能。
PLoS One. 2012;7(4):e35469. doi: 10.1371/journal.pone.0035469. Epub 2012 Apr 16.
8
Prevalence of cervical cancer and pre-cancerous lesions among unscreened Women in Kumasi, Ghana.加纳库马西未接受筛查女性中宫颈癌及癌前病变的患病率
Medicine (Baltimore). 2019 Mar;98(13):e14600. doi: 10.1097/MD.0000000000014600.
9
Effectiveness of cervical screening after age 60 years according to screening history: Nationwide cohort study in Sweden.根据筛查史评估60岁及以上女性宫颈筛查的有效性:瑞典全国队列研究
PLoS Med. 2017 Oct 24;14(10):e1002414. doi: 10.1371/journal.pmed.1002414. eCollection 2017 Oct.
10
Cervical Cancer in Women with Normal Papanicolaou Tests: A Korean Nationwide Cohort Study.正常巴氏涂片检查女性中的宫颈癌:一项韩国全国队列研究。
Cancer Res Treat. 2021 Jul;53(3):813-818. doi: 10.4143/crt.2020.826. Epub 2020 Dec 10.

引用本文的文献

1
Incidence and survival of gynecologic cancer including cervical, uterine, ovarian, vaginal, vulvar cancer and gestational trophoblastic neoplasia in Korea, 1999-2019: Korea Central Cancer Registry.1999 - 2019年韩国妇科癌症(包括宫颈癌、子宫癌、卵巢癌、阴道癌、外阴癌和妊娠滋养细胞肿瘤)的发病率和生存率:韩国中央癌症登记处
Obstet Gynecol Sci. 2023 Nov;66(6):545-561. doi: 10.5468/ogs.23208. Epub 2023 Oct 27.
2
Strategic Significance of Low Viral Load of Human Papillomavirus in Uterine Cervical Cytology Specimens.人乳头瘤病毒低病毒载量在子宫颈细胞学标本中的战略意义
Diagnostics (Basel). 2022 Jul 31;12(8):1855. doi: 10.3390/diagnostics12081855.
3

本文引用的文献

1
Impact of the Australian National Cervical Screening Program in women of different ages.澳大利亚国家宫颈癌筛查计划对不同年龄女性的影响。
Med J Aust. 2016 Oct 17;205(8):359-364. doi: 10.5694/mja16.00289.
2
Cervical screening in women over 65. PRO: Are we asking the right question?65岁以上女性的宫颈癌筛查。正方观点:我们问对问题了吗?
Gynecol Oncol. 2016 Sep;142(3):381-2. doi: 10.1016/j.ygyno.2016.08.230.
3
Case-control study of cervical cancer and gynecologic screening: A SEER-Medicare analysis.宫颈癌与妇科筛查的病例对照研究:SEER-医疗保险分析。
Trends in cervical cancer incidence and mortality of young and middle adults in Japan.
日本中青年宫颈癌发病率和死亡率趋势。
Cancer Sci. 2022 May;113(5):1801-1807. doi: 10.1111/cas.15320. Epub 2022 Mar 15.
4
The Role of Sources and Types of Health Information in Shaping Health Literacy in Cervical Cancer Screening Among African Immigrant Women: A Mixed-Methods Study.《来源和健康信息类型在塑造非洲裔移民妇女宫颈癌筛查健康素养中的作用:一项混合方法研究》
Health Lit Res Pract. 2021 Apr;5(2):e96-e108. doi: 10.3928/24748307-20210322-01. Epub 2021 May 10.
5
Trend analysis of process quality indicators for the Korean National Cervical Cancer Screening Program from 2005 to 2013.2005 年至 2013 年韩国国家宫颈癌筛查计划过程质量指标的趋势分析。
J Gynecol Oncol. 2021 Jan;32(1):e14. doi: 10.3802/jgo.2021.32.e14. Epub 2020 Dec 7.
6
Trends in Cancer Screening Rates among Korean Men and Women: Results of the Korean National Cancer Screening Survey, 2004-2018.韩国男性和女性癌症筛查率趋势:2004-2018 年韩国国家癌症筛查调查结果。
Cancer Res Treat. 2021 Apr;53(2):330-338. doi: 10.4143/crt.2020.263. Epub 2020 Oct 20.
7
Comparison of papanicolaou smear and human papillomavirus (HPV) test as cervical screening tools: can we rely on HPV test alone as a screening method? An 11-year retrospective experience at a single institution.巴氏涂片检查与人乳头瘤病毒(HPV)检测作为宫颈癌筛查工具的比较:我们能否仅依靠HPV检测作为一种筛查方法?来自单一机构的11年回顾性经验。
J Pathol Transl Med. 2020 Jan;54(1):112-118. doi: 10.4132/jptm.2019.11.29. Epub 2020 Jan 15.
8
Carcinogenic risk of human papillomavirus (HPV) genotypes and potential effects of HPV vaccines in Korea.人乳头瘤病毒(HPV)基因型的致癌风险及在韩国 HPV 疫苗的潜在影响。
Sci Rep. 2019 Aug 29;9(1):12556. doi: 10.1038/s41598-019-49060-w.
9
Prognostic significance of pretreatment lymphocyte percentage and age at diagnosis in patients with locally advanced cervical cancer treated with definite radiotherapy.局部晚期宫颈癌患者接受根治性放疗时,治疗前淋巴细胞百分比及诊断时年龄的预后意义。
Obstet Gynecol Sci. 2019 Jan;62(1):35-45. doi: 10.5468/ogs.2019.62.1.35. Epub 2018 Dec 3.
10
Burden of Human papillomavirus (HPV)-related disease and potential impact of HPV vaccines in the Republic of Korea.韩国人乳头瘤病毒(HPV)相关疾病负担及HPV疫苗的潜在影响。
Papillomavirus Res. 2019 Jun;7:26-42. doi: 10.1016/j.pvr.2018.12.002. Epub 2018 Dec 30.
Gynecol Oncol. 2016 Sep;142(3):395-400. doi: 10.1016/j.ygyno.2016.06.016. Epub 2016 Jul 4.
4
Cancer screening in the United States, 2016: A review of current American Cancer Society guidelines and current issues in cancer screening.美国 2016 年癌症筛查:对当前美国癌症协会指南和癌症筛查当前问题的回顾。
CA Cancer J Clin. 2016 Mar-Apr;66(2):96-114. doi: 10.3322/caac.21336. Epub 2016 Jan 21.
5
The Korean guideline for cervical cancer screening.韩国宫颈癌筛查指南。
J Gynecol Oncol. 2015 Jul;26(3):232-9. doi: 10.3802/jgo.2015.26.3.232.
6
Changing trends in the incidence (1999-2011) and mortality (1983-2013) of cervical cancer in the Republic of Korea.韩国宫颈癌发病率(1999 - 2011年)及死亡率(1983 - 2013年)的变化趋势
Epidemiol Health. 2015 May 29;37:e2015024. doi: 10.4178/epih/e2015024. eCollection 2015.
7
Trends in Cancer Screening Rates among Korean Men and Women: Results of the Korean National Cancer Screening Survey, 2004-2013.韩国男性和女性癌症筛查率的趋势:2004 - 2013年韩国全国癌症筛查调查结果
Cancer Res Treat. 2016 Jan;48(1):1-10. doi: 10.4143/crt.2014.204. Epub 2015 Apr 15.
8
Cervical cancer screening in Europe: Quality assurance and organisation of programmes.欧洲的宫颈癌筛查:项目的质量保证与组织
Eur J Cancer. 2015 May;51(8):950-68. doi: 10.1016/j.ejca.2015.03.008. Epub 2015 Mar 25.
9
The association between cervical cancer screening and mortality from cervical cancer: a population based case-control study.宫颈癌筛查与宫颈癌死亡率之间的关联:一项基于人群的病例对照研究。
Gynecol Oncol. 2014 May;133(2):167-71. doi: 10.1016/j.ygyno.2014.02.037. Epub 2014 Feb 28.
10
Assessment of cervical cancer screening policy in Korea for women over age 65.韩国 65 岁以上女性宫颈癌筛查政策评估。
J Geriatr Oncol. 2013 Oct;4(4):382-7. doi: 10.1016/j.jgo.2013.03.001. Epub 2013 Jun 14.